These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 24814494)

  • 21. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation.
    Gatzoulis KA; Vouliotis AI; Tsiachris D; Salourou M; Archontakis S; Dilaveris P; Gialernios T; Arsenos P; Karystinos G; Sideris S; Kallikazaros I; Stefanadis C
    Circ Arrhythm Electrophysiol; 2013 Jun; 6(3):504-12. PubMed ID: 23588627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of implantable cardioverter defibrillator for primary vs secondary prevention of sudden death in patients with idiopathic dilated cardiomyopathy.
    Zecchin M; Di Lenarda A; Proclemer A; Faganello G; Facchin D; Petz E; Sinagra G
    Europace; 2004 Sep; 6(5):400-6. PubMed ID: 15294264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [14-year experience with implantable cardioverter/defibrillators: determination of prognosis and discharge behavior].
    Vester EG; Dees H; Dobran I; Hennersdorf M; Perings C; Heydthausen M; Winter J; Strauer BE
    Z Kardiol; 2000; 89 Suppl 3():194-205. PubMed ID: 10810803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and outcomes of peripartum versus nonperipartum cardiomyopathy in women using a wearable cardiac defibrillator.
    Saltzberg MT; Szymkiewicz S; Bianco NR
    J Card Fail; 2012 Jan; 18(1):21-7. PubMed ID: 22196837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of appropriate implantable cardioverter defibrillator (ICD) therapy in primary prevention patients with ischemic and nonischemic cardiomyopathy.
    Verma A; Sarak B; Kaplan AJ; Oosthuizen R; Beardsall M; Wulffhart Z; Higenbottam J; Khaykin Y
    Pacing Clin Electrophysiol; 2010 Mar; 33(3):320-9. PubMed ID: 19796352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel marker of persistent left ventricular systolic dysfunction in patients with peripartum cardiomyopathy: monocyte count- to- HDL cholesterol ratio.
    Ekizler FA; Cay S
    BMC Cardiovasc Disord; 2019 May; 19(1):114. PubMed ID: 31092205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Earlier detection can help avoid many serious complications of peripartum cardiomyopathy.
    Fett JD
    Future Cardiol; 2013 Nov; 9(6):809-16. PubMed ID: 24180539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The need to modify patient selection to improve the benefits of implantable cardioverter-defibrillator for primary prevention of sudden death in non-ischaemic dilated cardiomyopathy.
    Disertori M; Quintarelli S; Mazzola S; Favalli V; Narula N; Arbustini E
    Europace; 2013 Dec; 15(12):1693-701. PubMed ID: 23946316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of implantable cardioverter-defibrillator on left ventricular ejection fraction in patients with idiopathic dilated cardiomyopathy.
    Schaer B; Theuns DA; Sticherling C; Szili-Torok T; Osswald S; Jordaens L
    Am J Cardiol; 2010 Dec; 106(11):1640-5. PubMed ID: 21094367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy.
    Maron BJ; Spirito P; Ackerman MJ; Casey SA; Semsarian C; Estes NA; Shannon KM; Ashley EA; Day SM; Pacileo G; Formisano F; Devoto E; Anastasakis A; Bos JM; Woo A; Autore C; Pass RH; Boriani G; Garberich RF; Almquist AK; Russell MW; Boni L; Berger S; Maron MS; Link MS
    J Am Coll Cardiol; 2013 Apr; 61(14):1527-35. PubMed ID: 23500286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meta-analysis of Risk of Ventricular Arrhythmias After Improvement in Left Ventricular Ejection Fraction During Follow-Up in Patients With Primary Prevention Implantable Cardioverter Defibrillators.
    Smer A; Saurav A; Azzouz MS; Salih M; Ayan M; Abuzaid A; Akinapelli A; Kanmanthareddy A; Rosenfeld LE; Merchant FM; Abuissa H
    Am J Cardiol; 2017 Jul; 120(2):279-286. PubMed ID: 28532779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implantable Cardioverter-Defibrillator Placement for Primary Prevention in 2,346 Patients: Predictors of One-Year Survival.
    Merchant FM; Desai Y; Addish MA; Kelly K; Casey M; Goyal A; Leon AR; El-Chami MF
    Tex Heart Inst J; 2018 Aug; 45(4):221-225. PubMed ID: 30374229
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Arrhythmias in peripartum cardiomyopathy.
    Honigberg MC; Givertz MM
    Card Electrophysiol Clin; 2015 Jun; 7(2):309-17. PubMed ID: 26002395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ventricular arrhythmias among implantable cardioverter-defibrillator recipients for primary prevention: impact of chronic total coronary occlusion (VACTO Primary Study).
    Nombela-Franco L; Mitroi CD; Fernández-Lozano I; García-Touchard A; Toquero J; Castro-Urda V; Fernández-Diaz JA; Perez-Pereira E; Beltrán-Correas P; Segovia J; Werner GS; Javier G; Luis AP
    Circ Arrhythm Electrophysiol; 2012 Feb; 5(1):147-54. PubMed ID: 22205684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Usefulness of sleep-disordered breathing to predict occurrence of appropriate and inappropriate implantable-cardioverter defibrillator therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death.
    Kreuz J; Skowasch D; Horlbeck F; Atzinger C; Schrickel JW; Lorenzen H; Nickenig G; Schwab JO
    Am J Cardiol; 2013 May; 111(9):1319-23. PubMed ID: 23411108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arrhythmic Risk Following Recovery of Left Ventricular Ejection Fraction in Patients with Primary Prevention ICD.
    Berthelot-Richer M; Bonenfant F; Clavel MA; Farand P; Philippon F; Ayala-Paredes F; Essadiqi B; Badra-Verdu MG; Roux JF
    Pacing Clin Electrophysiol; 2016 Jul; 39(7):680-9. PubMed ID: 27062583
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implantable cardioverter defibrillators in patients with valvular cardiomyopathy.
    Valles AG; Khawaja FJ; Gersh BJ; Enriquez-Sarano M; Friedman PA; Park SJ; Hodge DO; Cha YM
    J Cardiovasc Electrophysiol; 2012 Dec; 23(12):1326-32. PubMed ID: 23130974
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Associations between scar characteristics by cardiac magnetic resonance and changes in left ventricular ejection fraction in primary prevention defibrillator recipients.
    Zhang Y; Guallar E; Weiss RG; Stillabower M; Gerstenblith G; Tomaselli GF; Wu KC
    Heart Rhythm; 2016 Aug; 13(8):1661-6. PubMed ID: 27108939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Impact of Cardiac Magnetic Resonance Imaging Versus Echocardiography-Guided Patient Selection for Primary Prevention Implantable Cardioverter Defibrillator Therapy.
    Rijnierse MT; van der Lingen AL; Weiland MT; de Haan S; Nijveldt R; Beek AM; van Rossum AC; Allaart CP
    Am J Cardiol; 2015 Aug; 116(3):406-12. PubMed ID: 26050137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.